Short-term hormonal modulation with mifepristone does not induce oncogenic changes in the endometrium of BRCA1/2 pathogenic variant carriers
{{output}}
Background: Progesterone receptor antagonists such as mifepristone have emerged as candidates for breast cancer prevention, particularly in high-risk populations such as BRCA1/2 pathogenic variant carriers. However, their impact ... ...
